Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CMB.AU
- Price
- 0.53
- Stock movement up
- +0.04 (9.38%)
- Company name
- Cambium Bio Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 12.00M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 28.05%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-30
DIVIDENDS
CMB.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.49 |
| Daily high | 0.53 |
| Daily low | 0.49 |
| Daily Volume | 7K |
| All-time high | 58.65 |
| 1y analyst estimate | 2.57 |
| Beta | -0.24 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CMB.AU | S&P500 | |
| Current price drop from All-time high | -99.10% | -1.10% |
| Highest price drop | -99.68% | -19.00% |
| Date of highest drop | 23 May 2025 | 8 Apr 2025 |
| Avg drop from high | -99.36% | -2.76% |
| Avg time to new high | - | 5 days |
| Max time to new high | 269 days | 89 days |
COMPANY DETAILS
Marketcap
12.00M
Marketcap category
Small-cap
Description
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found